Lipella to Proceed with Phase 2b Clinical Trial in Hemorrhagic Cystitis

Clinical stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) has received Type C meeting guidance from the FDA regarding the design of its Phase 2b clinical trial. The FDA provided preliminary agreement on Lipella’s overall trial design, including objectives, safety monitoring, control group monitoring, the dosing protocol, the primary efficacy endpoint, and sample size considerations. The… [Read More]

SS Innovations International (SSII) Furthers Market Penetration Strategy with 100th Cardiac Robotic Procedure

Surgical robotics company, SS Innovations International, Inc. (SSII) has announced a milestone for robotic cardiac surgery as its SSi Mantra Surgical Robotic System has surpassed its 100th cardiac surgery. The company who is dedicated to making world class robotic surgery affordable and accessible, globally implements the world’s only comprehensive robotic cardiac surgery program. Additionally, its… [Read More]

NKGen to Progress Alzheimer’s Candidate into Phase 2; Shares Surge 75%

Shares in biotechnology company, NKGen Biotech (Nasdaq: NKGN) soared more than 75% in morning trading on Monday after the company announced that its lead candidate SNK01 has received Safety Review Committee clearance to progress into Phase 2 clinical development. The company is evaluating SNK01, a novel cell-based, patient-specific expanded autologous natural killer cell, immunotherapeutic drug… [Read More]

BranchOut Food Achieves Record First Quarter

Leading food technology company, BranchOut Food Inc. (Nasdaq: BOF), has reported record financial results for the first quarter ending March 31, 2024. The company achieved revenue growth of 1,407%, year over year, reaching $1.47 million. Additionally, BranchOut Food achieved a gross margin of 19% in Q1 2024, a significant improvement from -3% in Q1 2023…. [Read More]

MIRA Pharmaceuticals Advances Potential First At-Home Ketamine Treatment for PTSD

MIRA Pharmaceuticals (Nasdaq: MIRA) is advancing closer to clinical development of what could potentially be the first at-home ketamine-based treatment for post-traumatic stress disorder (PTSD). MIRA is evaluating Ketamir-2, its differentiated oral ketamine analog, for the treatment of severe PTSD, along with other mental health disorders and neuropathic pain indications. The company’s share price soared… [Read More]

What’s Next in the Great GLP-1 Race?

 Roche Holding (RHHBY) joined the race to commercialize its own GLP-1 (glucagon-like peptide-1) receptor agonist drug this week, announcing that its dual-agonist asset, CT-388, had achieved statistically significant weight loss in people with obesity in an early stage trial. At week 24 of treatment, 45% of participants achieved weight loss of approximately 20% of their… [Read More]